{
  "ticker": "EVE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966503",
  "id": "02966503",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250707",
  "time": "0849",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljh5z69x4l6g.pdf",
  "summary": "- **First commercial purchase order submitted** for Dyspro\u2122, EVE\u2019s proprietary cannabinoid-based pharmaceutical product for dysmenorrhoea.  \n- **Manufacturing underway** at GMP-certified Australian facility; product expected for **distribution within 5 weeks**.  \n- **Market opportunity**: Dysmenorrhoea treatment market projected to reach **USD 20 billion globally by 2035** (5.73% CAGR).  \n- **Regulatory pathway complete** \u2013 existing prescriber network authorized, enabling rapid commercial uptake.  \n- **Distribution partnership** with TeleDocs Clinic secured for digital prescribing and fulfillment; other logistics partners under review.  \n- **No capital raising or financial details** disclosed; operational milestone announcement only.  \n\n*Prioritized material catalysts: product launch timeline, market size, and prescriber readiness.*",
  "usage": {
    "prompt_tokens": 1831,
    "completion_tokens": 172,
    "total_tokens": 2003,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T22:58:57.642741"
}